Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAlliance Pharma Regulatory News (APH)

  • This share is currently suspended. It was suspended at a price of 64.70
  • There is currently no data for APH

Directorate Changes

18 May 2022 07:00

RNS Number : 8511L
Alliance Pharma PLC
18 May 2022
 

 

For immediate release

18 May 2022

 

 

 

ALLIANCE PHARMA

("Alliance" or the "Group")

 

Directorate changes

 

Alliance Pharma plc (AIM: APH), the international healthcare group, announces that, in line with good corporate governance, David Cook, Alliance's Chair, will be stepping down next year, following the AGM in May 2023, after serving on the Board for nine years.

 

Jo LeCouilliard, currently a Non-Executive Director on the Board of Alliance, will become Chair following the AGM in May 2023.

 

Jo LeCouilliard joined Alliance as a Non-Executive Director on 1 January 2019. She brings over 25 years of international healthcare management experience through her career at GlaxoSmithKline where, amongst other roles, she headed the US vaccines business and the Asia Pacific Pharmaceuticals business. Jo is a Chartered Accountant and is currently a Non-Executive Director at Circassia Group plc, Indivior plc and Recordati S.p.a.

 

David Cook commented: "Alliance has developed significantly over the time I have been with the business, building an international footprint and transitioning to focus on consumer healthcare brands. I am confident that the Company has a bright future, led by an outstanding senior management team. Jo has been an invaluable Board member over the past three and a half years and we are delighted that she has agreed to chair the Board as the Company continues on its growth trajectory. I look forward to working closely with her during my remaining time at Alliance."

 

Jo LeCouilliard commented: "I am delighted to be taking on the position of Chair following next year's AGM. I have been really impressed by Alliance's strong management team and strategy over my last three and a half years on the Board. The Company has successfully executed a number of strategic consumer healthcare acquisitons and has built a solid international infrastructure. I look forward to leading the Board in taking the Company forward."

 

 

For further information:

 

Alliance Pharma plc

+ 44 (0)1249 466966

Cora McCallum, Head of Investor Relations & Corporate Communications

+ 44 (0)1249 705168

ir@allianceph.com

 

 

 

Buchanan

+ 44 (0)20 7466 5000

Mark Court / Sophie Wills / Hannah Ratcliff

 

alliancepharma@buchanan.uk.com

 

 

 

Numis Securities Limited

+ 44 (0)20 7260 1000

Nominated Adviser: Freddie Barnfield / Duncan Monteith

 

Corporate Broking: James Black

 

 

 

Investec Bank plc

+ 44 (0)20 7597 5970

Corporate Finance: Daniel Adams

 

Corporate Broking: Patrick Robb

 

 

 

About Alliance

 

Alliance Pharma plc (AIM: APH) is an international healthcare group. Our purpose is to improve the lives of consumers and patients through making available a range of clinically valuable healthcare products.

Our core focus is on the marketing of Consumer Healthcare brands, complemented by a smaller Prescription Medicines business. In total, we hold marketing rights to around 80 brands, with revenues generated from a mix of direct, distributor and e-commerce sales.

Headquartered in the UK, the Group employs around 250 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics operations, we remain asset-light and focused on maximising the value of our brands.

For more information on Alliance, please visit our websitewww.alliancepharmaceuticals.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAGPUWWAUPPGMM
Date   Source Headline
22nd Dec 20177:00 amRNSBlock Listing Six Monthly Return
4th Dec 20177:00 amRNSProposed acquisition of Vamousse
4th Dec 20177:00 amRNSTender Offer to Shareholders and Notice of Meeting
1st Dec 20177:00 amRNSAcquisition of AmetopT
17th Oct 20179:14 amRNSHardman Research: Kelo-cote international sales
13th Sep 20177:00 amRNSInterim Results
6th Sep 20177:00 amRNSAppointment of Joint Corporate Broker
1st Aug 20177:00 amRNSNotification of Interim Results
28th Jul 20174:21 pmRNSUpdate on Diclectin
25th Jul 20175:40 pmRNSChanges to interests of a significant shareholder
25th Jul 20175:34 pmRNSChanges to interests of a significant shareholder
18th Jul 20177:00 amRNSHalf Year Trading Update
3rd Jul 20172:29 pmRNSChanges to interests of a significant shareholder
26th Jun 20175:31 pmRNSChanges to interests of a significant shareholder
22nd Jun 20175:22 pmRNSChanges to interests of a significant shareholder
21st Jun 20172:53 pmRNSApplication for block admission
19th Jun 20173:16 pmRNSChanges to interests of a significant shareholder
19th Jun 20172:37 pmRNSApplication for admission
14th Jun 20174:54 pmRNSApplication for admission
25th May 20173:20 pmRNSChanges to interests of a significant shareholder
25th May 201711:00 amRNSResult of AGM
25th May 20177:15 amRNSHardman Res.: Transformed International Business
25th May 20177:00 amRNSAGM Statement
22nd May 201710:10 amRNSApplication for admission
9th May 20171:50 pmRNSCorrection: Application for admission
8th May 20172:30 pmRNSApplication for admission
5th May 20176:10 pmRNSApplication for admission
5th May 20177:00 amRNSChanges to interests of a significant shareholder
5th May 20177:00 amRNSChanges to interests of a significant shareholder
4th May 20171:30 pmRNSChanges to interests of a significant shareholder
28th Apr 201712:15 pmRNSAnnual Report and AGM Notice
28th Apr 20179:45 amRNSChanges to interests of a significant shareholder
24th Apr 201711:33 amRNSChanges to interests of a significant shareholder
5th Apr 20171:30 pmRNSNotification of Major Interest in Shares
31st Mar 20174:59 pmRNSApplication for admission
29th Mar 20177:00 amRNSFull Year Results
21st Mar 20177:00 amRNSSettlement Agreement with Sinclair Pharma plc
2nd Mar 20177:00 amRNSNotification of Preliminary Results
14th Feb 20175:31 pmRNSPDMR shareholding
14th Feb 20175:30 pmRNSApplication for admission
7th Feb 20179:05 amRNSChanges to interests of a significant shareholder
31st Jan 20177:00 amRNSExercise of Share Options
25th Jan 20177:15 amRNSHardman Research: Potential of Diclectin
23rd Jan 20177:00 amRNSPre-Close Trading Update
16th Dec 20164:00 pmRNSExercise of Share Options
15th Dec 20164:50 pmRNSExercise of Share Options
12th Dec 20169:19 amRNSExercise of Share Options
9th Dec 201611:45 amRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
8th Dec 20167:00 amRNSCapital Markets Event
30th Nov 20164:00 pmRNSNotification of Major Interest in Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.